CASI Pharmaceuticals, Inc.
BEIJING, F4
This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.
What changed
NIH R34 · $0.2M · PEth-based contingency management for alcohol use disorder in patient with alcohol-associated liver disease
2mo agoNew grantMay 14, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 89 out of 100, unchanged since the last recompute.
Accelerating: several high-weight events landed recently.
Runway (estimate)
The model puts this company near the end of its last raise.
Stage
Phase II
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
R34 · $226k · non-dilutive
May 11, 2026MASSACHUSETTS GENERAL HOSPITAL · PI ZHANG, WEI · NIAAA · award ends Apr 30, 2029 · PEth-based contingency management for alcohol use disorder in patient with alcohol-associated liver disease
NIH RePORTER · NIH RePORTER 11304218 (opens the source filing in a new tab)
- Filing
Form D · $5.0M
Apr 28, 2026CASI Pharmaceuticals, Inc. · private raise, self-reported by the issuer
SEC EDGAR · 0001962738-26-000004 (opens the source filing in a new tab)
- Filing
Form D · $5.0M
Feb 26, 2026CASI Pharmaceuticals, Inc. · private raise, self-reported by the issuer
SEC EDGAR · 0001962738-26-000003 (opens the source filing in a new tab)
- Filing
Form D · $5.0M
Jan 28, 2026CASI Pharmaceuticals, Inc. · private raise, self-reported by the issuer
SEC EDGAR · 0001962738-26-000001 (opens the source filing in a new tab)
- Filing
Form D · $5.0M
Jan 28, 2026CASI Pharmaceuticals, Inc. · private raise, self-reported by the issuer
SEC EDGAR · 0001962738-26-000002 (opens the source filing in a new tab)
- Trial
PHASE2 registered
Sep 10, 2025Hepatocellular Carcinoma · NOT_YET_RECRUITING · sponsor: Tianjin Medical University Cancer Institute and Hospital · Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
ClinicalTrials.gov · NCT07157306 (opens the source filing in a new tab)
- Trial
PHASE2 registered
May 10, 2025Primary Intraocular Lymphoma · NOT_YET_RECRUITING · sponsor: Peking Union Medical College Hospital · ZR-MTX for PIOL Phase II Trial
ClinicalTrials.gov · NCT06973811 (opens the source filing in a new tab)
- Trial
Study registered
Jan 9, 2019Multiple Ground Glass Opacities (GGOs) · ACTIVE_NOT_RECRUITING · sponsor: Memorial Sloan Kettering Cancer Center · A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)
ClinicalTrials.gov · NCT03802981 (opens the source filing in a new tab)
- Trial
Study registered
Jan 1, 2010Resectable Simultaneous Colorectal Cancer Liver Metastasis · COMPLETED · sponsor: Changhai Hospital · The Outcomes of Laparoscopic Hybrid Surgery Versus Totally Open Surgery
ClinicalTrials.gov · NCT06550700 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources